Tempus AI Seen As Sequencing Winner In Moderna-Merck Cancer Vaccine Push

Moderna and Merck’s personalized cancer vaccines have added more than $50 billion in combined market value, and investors are now eyeing the sequencing work behind each dose. According to BeInCrypto, Tempus AI said it would serve as the sequencing partner if the Moderna-Merck vaccine wins regulatory approval, while Piper Sandler and BTIG’s Mark Massaro estimate annual sequencing revenue could range from at least $50 million to more than $600 million. The bigger prize may be MRD testing, which monitors recurrence after treatment.